News

Virginia Medtech Company Is Awarded $13M Contract Continuation from the Navy

NIRSense Inc., headquartered in Richmond, Virginia, won an expansion to a competitively-awarded contract this month to build fieldable physiology monitors for the US Navy. NIRSense has been working with the Department of Defense since 2019 to build medical-grade physiology monitors to support US warfighter safety, performance, and medical care in training and operations. “NIRSense has developed unmatched capabilities to provide physiological monitoring in challenging environments faced by our soldiers, sailors, airmen and marines at the direction of Navy, Army, and Air Force stakeholders”, said NIRSense CEO Casey Boutwell, PhD. Future battlefields are expected to produce new challenges for the military health system requiring the DoD to look for new solutions in training safety and casualty care. Dr. Boutwell continued; “We are honored to be selected to contribute to the critical mission of safely training and caring for one of our nation’s most valuable assets, the American warfighter.”

The contract continuation was funded by Naval Medical Research Command-Naval Advanced Medical Development (NMRC-NAMD) through the Medical Technology Enterprise Consortium (MTEC). NIRSense is actively hiring design, engineering, and management talent in offices in Virginia and North Carolina.

Learn more here.

Recent News

09/17/2026

Rivanna Announces New CMS Procedure Code for Computer-aided Neuraxial Guidance

RIVANNA®, developer of AI-enabled clinical decision-support solutions, today announced that the Centers for Medicare & Medicaid Services (CMS) has established ICD-10-PCS code XEZU3HC, effective for inpatient discharges beginning October 1, 2026. The code identifies computer-aided intraprocedural navigation in the spinal canal using ultrasound imaging with continuous needle tracking via a percutaneous approach during neuraxial anesthesia.

09/17/2026

From Lab to Three Continents: Agrospheres and FMC Corporation Advance Bioinsecticide Pipeline into Global Field Trials

AgroSpheres, a biotechnology company pioneering breakthroughs in sustainable crop protection and FMC Corporation (NYSE: FMC), a global leader in agricultural sciences, today announced a significant advancement in its ongoing collaboration. Two proprietary RNA-based biomolecule candidates from AgroSpheres’ pipeline are now entering global field trial development, marking the transition from discovery into real-world testing across three

09/15/2026

Jazz Pharmaceuticals Completes Acquisition of Actio Biosciences

Jazz Pharmaceuticals plc (Nasdaq: JAZZ) (“Jazz” or the “Company”) today announced the successful completion of its acquisition of privately-held Actio Biosciences, Inc. (“Actio”) for $820 million upfront. Actio is now a wholly-owned subsidiary of Jazz. “ABS-1230 holds the promise of being a transformative, first-in-class therapy for individuals living with KCNT1-related epilepsy,” said Renee Gala, president and